Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

▤ Summary

Quest Diagnostics won New York State approval for its Haystack MRD ctDNA test, expanding patient access for monitoring residual or recurring solid-tumor disease. The approval allows the test to be used in all 50 U.S. states after clearing New York's strict laboratory review process. Quest says the test can help oncologists detect recurrence earlier and assess treatment response with greater confidence. The company also points to clinical evidence from a study at Memorial Sloan Kettering that showed the test can identify response faster than imaging in a dMMR solid tumor setting. Haystack Oncology continues to position the assay for clinical use, trials, and biopharmaceutical partnerships.

▦ Linked Companies